On October 13, the pharmaceutical sector changed, and many stocks went up and down!

【Pharmaceutical Network Pharmaceutical Stock Market】On October 13, the pharmaceutical sector changed, in terms of individual stocks, Shuangcheng Pharmaceutical, Osaikang, Huadong Pharmaceutical, Baihua Pharmaceutical rose by more than 13%, in addition, WuXi AppTec, Kelleyin, Sunshine Novo, Medici, Fuxiang Pharmaceutical, WuXi AppTec, PharmaBlock Technology, Jiuzhou Pharmaceutical, Junshi Biologics, Changchun High-tech, Addison Pharmaceutical, Sailun Biologics, etc
.
have followed.
Specifically, as of 10:13 on October 13, Shuangcheng Pharmaceutical rose 9.
98%, quoting 6.
06 yuan, with a turnover of 115 million yuan and a turnover rate of 4.
84%.

On the news, the company said on the interactive platform on October 12 in response to investors' sales of the US business that the company's injection bivalirudine has occupied a large market share in the United States after successfully challenging the original patent; In August this year, the first batch of eptifibatide injection was also successfully exported
.
Data show that bivalirudin is a direct thrombin inhibitor for injection, which has the characteristics
of reversible action, short half-life, and does not cause thrombocytopenia.
Bivalirudin for injection is indicated as an anticoagulant for percutaneous transluminal coronary angioplasty (PTCA) and percutaneous coronary intervention (PCI) in adults, and for patients
with heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombotic syndrome (HITTS) in PCI.
According to previous data, the sales of bivalirudin for injection in the US market in 2018 have reached 81.
8 million US dollars.

Etifibatide injection is indicated for anticoagulation in patients with acute coronary syndrome, including patients receiving drug therapy and patients undergoing percutaneous coronary intervention PCI, and also for patients undergoing percutaneous coronary intervention PCI, including patients
undergoing intracoronary stenting.
In September 2021, ANDA of eptifibatide injection (20mg/10ml) obtained marketing approval
from the US FDA.
In April this year, the company announced that its application for a simple new drug supplement for eptifibatide injection (specification 75mg/100mL) submitted to the US FDA has been approved
by the US FDA 。 In addition, as of 10:13 on October 13, among the stocks that rose and stopped, Aosikang quoted 8.
47 yuan, with a turnover of 25.
68 million yuan and a turnover rate of 0.
33%; Huadong Pharmaceutical quoted 42.
36 yuan, with a turnover of 769 million yuan and a turnover rate of 1.
05%; Baihua Pharmaceutical quoted 6.
51 yuan, with a turnover of 54.
07 million yuan and a turnover rate of 2.
26%; Luoxin Pharmaceutical quoted 7.
60 yuan, with a turnover of 67.
24 million and a turnover rate of 1.
82%.

From the perspective of subdivision track, the CRO sector performed well on the 13th, of which WuXi AppTec rose nearly 8%, Porton shares rose more than 7%, and Clarion, Jiuzhou Pharmaceutical, Medici, Kanglong Chemical, and Tigermed all rose
sharply.
On the news, WuXi AppTec announced on the evening of October 12 that it expects a net profit of 7.
38 billion yuan in the first three quarters, a year-on-year increase of 107.
12%, which greatly exceeds market expectations and shows a high prosperity
.
Zhongtai Securities believes that CRO company fundamentals are still strong, valuations are at historically low levels, and growth is expected to accelerate after the recovery of the epidemic
.
The fundamentals of the sector remain strong, and the indicators are frequently
highlighted.
Affected by geopolitical games, investment and financing fluctuations, transfer trends, repeated epidemics, etc.
, the valuation of the CRO sector returned to a historical low, but the fundamentals of the sector in the first half of 2022 remained strong, mainly benefiting from five aspects: continued high performance; Project transfer continues; Operational efficiency continued to improve: the average human efficiency of CRO in half a year increased to 288,000 yuan/person (+8.
8%); Capacity expansion continues; Concentration continues to increase: the top three companies accounted for 55.
3% (+4.
2pp).

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.